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Abstract 
Purpose of review: This review provides an overview of recent progress within work centred around 
the ‘International schedule for the integrated assessment and staging of care for dementia’ (IDEAL 
schedule), and places it within the context of recent work around other staging models for 
dementia. 
Recent findings: The IDEAL schedule assesses the severity of dementia across seven dimensions. A 
‘Menu of care options’ of recommended priorities for interventions accompanies the schedule. A 
user manual for the schedule has just been published. Other staging models for dementia include 
those based on biomarkers, such as in the recently published research framework for Alzheimer’s 
disease by the National Institute on Aging and Alzheimer’s Association (NIA-AA), or those based on 
specific aspects of dementia, principally cognitive impairment. 
Summary: The IDEAL schedule is a global staging model to guide the organisation of dementia care. 
The schedule covers a range of domains that extend beyond cognitive functioning and include care 
needs; it is applicable to all types and stages of dementia; and can be used by any health care 
professional, both within clinical practice and research. The schedule is not in opposition to, or is 
even complementary to, other staging models for dementia. 
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Introduction 
This review is centred around work that has been ongoing by the International Dementia Alliance 
(IDEAL) group. Our group, formed in 2002 (formerly European Dementia Consensus Network 
(EDCON)), consists of European specialists from various disciplines with experience in the research, 
diagnosis and care of patients with dementia.  
The IDEAL group started to develop a global staging model in 2011 because of our concerns around 
the increasing prevalence and burden of dementia [1, 2], as well as the lack of organisation and 
coordination of dementia care within Europe [3]. In addition, staging, in which diseases or disorders 
are assessed according to their different severity levels, had led to an improvement in care for other 
physical and mental disorders, such as cancer and renal-disease [4-9], bipolar disorder [10-14], 
schizophrenia [10, 12, 15-17], and depression [10, 16-19]. However, our group had found through a 
systematic review that there was a lack of clinical staging scales for dementia that were able to 
monitor disease progress and health care needs, were sufficiently validated, showed adequate 
reliability, were applicable during the entire course of the disease, and were applicable cross-
culturally [20], as well as being able to assess both dementia-related and non-dementia-related care 
needs.  
The IDEAL group named our global staging model the ‘International schedule for the integrated 
assessment and staging of care for dementia’ (IDEAL schedule), and our aim was for it to be used to 
organise the care of people with dementia, and thus guide the organisation of dementia care. The 
five criteria initially laid out by our group for the IDEAL schedule were: i) ease of use; ii) reliability; iii) 
‘goodness of fit’, i.e. for it to record the relevant facts about the patient’s condition; iv) for it to have 
been tried and found useful in different cultures and services; and v) for it to have a direct link to 
suggestions concerning treatment. The IDEAL schedule is also applicable to all types and stages of 
dementia, and can be used either within clinical practice or research. 
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This narrative review provides an overview of recent progress within this work, and places it within 
the wider research and clinical context of developments within staging for dementia over the last 18 
months. Relevant publications have been included in this review that were known to the author 
group, as well as those identified through a non-systematic search of the literature. 
 
Recent work on the IDEAL schedule 
The IDEAL schedule consists of seven dimensions: activities of daily living; physical health; cognitive 
functioning; behavioural and psychological symptoms; social support; informal care (which includes 
two sub-dimensions: time spent on care by informal carer; and carer stress); and formal professional 
care (which includes three sub-dimensions: total number of hours of formal professional care 
received; total number of hours of formal professional care needed; and additional dementia-
related care needed). Each of the seven dimensions is rated on a six-point scale from 0 to 5, with a 
higher score reflecting a higher level of abnormality/severity. Each dimension has a set of anchor 
points, which assist the user of the schedule in rating the different dimensions appropriately, and 
which are described in more detail in a glossary that accompanies the schedule. A total sum score, 
which can range between 0 and 35, can also be calculated by adding up the individual scores of the 
seven dimensions. The IDEAL schedule may thereby give a preliminary indication of the overall level 
of care required (denoted by the total sum score), as well as provide more detailed information 
about the symptoms of dementia and requirements for care (denoted by the seven individual 
dimensions). 
The IDEAL schedule is also accompanied by a ‘Menu of care options’, which entails recommended 
priorities for interventions (though not all possible interventions) for each of the different symptoms 
and severity patterns of dementia, as measured by the schedule. The aim of this ‘Menu of care 
options’ is to enable practitioners to choose appropriate interventions, depending on the patient’s 
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symptomatology and severity levels, as well as their setting and the resources they have available. 
The ‘Menu of care options’ includes five categories of interventions: Individualized psychosocial 
support, Drugs, Education, Additional health problems, and Living arrangements. Within each of 
these categories, there are listed examples of potential interventions according to the different 
severity levels of dementia (as measured by the IDEAL schedule), as well as whether the intensity of 
care is likely to be low, medium or high for each of the categories.  
The IDEAL schedule was originally published in preliminary form as part of a journal article on its 
development and reliability testing across nine countries (France; Germany; Italy; Netherlands; 
Romania; Serbia; South Korea; Spain; and Turkey) [21]. During this study, the IDEAL schedule was 
shown to have good inter-rater reliability when two raters (one interviewer, one silent observer) 
separately completed the schedule based on an interview with a total of 209 dementia patients and 
their informal caregivers (intraclass correlation coefficients (ICCs) for total IDEAL sum scores ranged 
between 0.89 and 0.99 in the nine field-sites, and 84.4% of all ICCs were over 0.7 for the individual 
dimensions of the schedule). Face validity and content validity of the schedule were established 
through expert consensus of a wide range of professionals involved in dementia care in Europe 
about the schedule’s format and content (e.g. through focus group discussions) [21]. Following this,  
a paper was published on the inter-rater reliability of the schedule in Ireland (ICCs ranged between 
0.77 and 1.0 for the individual dimensions), as well as its criterion validity whereby the ‘cognitive 
functioning’ and ‘carer stress’ (sub-)dimensions of the IDEAL schedule, as well as its total sum score, 
were correlated with the Clinical Dementia Rating (CDR) scale (ρ=0.82 for ‘cognitive functioning’; 
ρ=0.77 for total sum score) and Zarit Burden interview respectively (ρ=0.56) as a measure of 
criterion validity [22]. A further study from the Netherlands reported on the development and 
validation of a version that is completed by informal caregivers, the IDEAL-IC, by correlating this new 
version with the original clinician-administered IDEAL schedule (r= 0.7) and the Clinical Dementia 
Rating sum of boxes (CDR-SB) (r=0.65) as a measure of construct validity [23]. In this latter study, 
correlation between the original IDEAL schedule and the CDR-SB was also very high (r=0.85) [23]. 
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This review is timely in that the IDEAL schedule has just been published as part of a detailed manual, 
which provides the reader with all information needed when learning to use the schedule [24]. This 
could be any health care professional with experience in the diagnosis, guidance or treatment of 
people with dementia. In addition, in the last 18 months, work has been completed on the reliability 
of the IDEAL schedule in a further seven countries (Brazil; China; Croatia; Hong Kong; India; 
Singapore; and Switzerland) with a total of 174 dementia patients and their caregivers, which found 
that the schedule had good inter-rater reliability and was easy to use across these different settings 
and with a variety of different types of health workers. This was complemented by a survey of 23 
professionals from 14 countries who had experience in use of the IDEAL schedule, which 
demonstrated the feasibility and acceptability of the schedule. A paper on this is forthcoming (by 
Semrau et al). There have also been publications on the reliability and validity of the schedule both 
in China [25] and Spain [26], which reported good results in these settings. Both of these studies 
confirmed the main psychometric properties of the original English version of the IDEAL schedule 
(China: ICC for total sum score for inter-rater reliability = 0.93; Spain: mean ICC for inter-rater 
reliability = 0.861, 85% of the ICCs over 0.8) and documented the convergent validity of individual 
items by correlating the total sum score of the IDEAL schedule with the CDR (ρ=0.72), CDR-SB 
(ρ=0.74), Mini-Mental State Examination (MMSE) (ρ=-0.65) and Caregiver Burden Inventory (CBI) 
(ρ=0.7) in China [25], and the CDR in Spain (r=0.63, r = between 0.4 and 0.84 for individual 
dimensions) [26]. In addition, both studies contributed further novel findings in that the one from 
Spain supported a latent construct consistent with the concept of ‘care needs’ by means of factor 
analysis [26], and the one from China reported test-retest reliability of the IDEAL schedule for the 
first time whereby the IDEAL schedule was completed by the same interviewer and silent rater a 
second time seven to ten days later with the same patients (interclass coefficient for the total IDEAL 
sum score was 0.95 for interviewers and 0.93 for silent raters) [25]. 
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A new research framework for Alzheimer’s disease 
In the last 18 months, one issue that is new and relevant to the staging and definition of dementia, 
and thereby the IDEAL schedule, is the staging proposed implicitly in the new research framework 
for Alzheimer’s disease by the National Institute on Aging and Alzheimer’s Association (NIA-AA) [27]. 
This model represents a shift in thinking about Alzheimer’s disease in that it involves the 
development of a staging system for the condition based on biological criteria, whereby it is defined 
within research (not clinical practice) by its underlying aggregate of neuropathologic changes, which 
can be established either through biomarkers in living persons or alternatively an autopsy post-
mortem, rather than the clinical signs and symptoms of the disease. Within this model, staging 
severity of Alzheimer’s disease is done via a combination of the grading of disease severity through 
use of biomarkers and the grading of severity of cognitive impairments [27]. Apart from the NIA-AA, 
other authors have also similarly published papers in the last 18 months, linking biomarkers to 
different stages of Alzheimer’s disease [28-30]. 
The IDEAL staging system is not in opposition to this present development of a staging model for 
Alzheimer’s dementia based on biological criteria. Indeed, the IDEAL schedule and the NIA-AA 
research framework share some similar goals, for example in terms of aiming to create a common 
language amongst professionals [24, 27]. However, the IDEAL staging model for dementia takes a 
different approach to the NIA-AA research framework in that it aims to help organise care for any 
type of dementia (not just Alzheimer’s disease) regardless of the clinical presentation and underlying 
aetiology, and covers not only the degree of cognitive impairment, but also related behavioural and 
psychological symptoms and functional impairment, and all relevant domains associated with 
dementia and care needs. Furthermore, the NIA-AA research framework is restricted to research, 
whereas the IDEAL schedule was primarily developed for clinical practice (though it is also applicable 
to research). The two approaches are therefore complementary, and indeed the NIA-AA 
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acknowledge that their research framework is not meant to restrict other models that do not use 
biomarkers [27]. 
There have been some criticisms of the NIA-AA research framework, for example that it is too 
restrictive in terms of basing the definition of Alzheimer’s disease purely on a biomarker profile 
without the requirement for corresponding symptoms; that the designated biomarkers are not 
sensitive or specific to the clinical diagnosis of dementia; and that – even though the framework is 
meant to apply to research only – it has implications far beyond that including within clinical practice 
[31]. 
 
Recent work on other staging tools 
An alternative approach that has been used within the staging of dementia is based on severity of 
cognitive impairment through use of established tools that measure cognition, such as the MMSE 
[32]. For example, previous work by Santabárbara et al (2016) [33] found an increased risk of 
dementia associated with the severity level of cognitive impairment, as measured by the MMSE. 
Within this model, agreed cut-off scores are used to differentiate between dementia severity stages. 
Recent work in the last 18 months has extended this staging model to other population groups. For 
instance, Chua et al (2018) [34] validated this approach within a multi-ethnic Asian population in 
Singapore; they found that the cut-off scores that they derived were lower than the conventional 
scores, and that scores differed between participants of different education levels, which is 
consistent with previous research [35]. The authors therefore concluded that MMSE cut-off staging 
scores need to be established according to the locality and specific population group [34]. 
Lima et al (2017) [36] evaluated the diagnostic validity of another tool that measures cognitive 
impairment, the CDR-SB. The authors looked at the instrument’s ability to detect and stage cognitive 
impairment amongst patients in Brazil with low educational attainment, and found the tool to have 
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good validity for this. The CDR is a well-established and widely used scale to measure the severity of 
cognitive impairments, ranging from normal functioning to severely impaired [37]. The CDR-SB 
provides an alternative, simpler way of calculating the global sum score of the CDR [36]. 
Also in Brazil, Lima-Silva et al (2018) [38] explored and found to be satisfactory the factor structure, 
internal consistency, reliability and convergent reliability of the Brazilian version of the 
Frontotemporal Dementia Rating Scale (FTD-FRS), which was originally developed in 2010 and 
includes six stages of severity, ranging from very mild to advanced/profound for frontotemporal 
dementia [39]. The FTD-FRS differs from the MMSE and CDR staging methods in that it measures 
functional deterioration across five domains that extend beyond cognitive functioning, including 
behaviour, outing and shopping, household chores, self-care and mobility. 
These staging approaches are again different but not in opposition to the IDEAL staging model. 
Whilst the MMSE and CDR staging methods are based purely on cognitive impairments, the IDEAL 
schedule takes a broader approach in that it covers not only cognitive functioning but a range of 
domains beyond that, including importantly staging of care needs. The MMSE and CDR can thus in 
fact be incorporated within IDEAL assessments, by providing information in regards to cognitive 
impairment; an assessment of cognitive impairment conducted through the MMSE or CDR could 
therefore map onto the ‘Cognitive functioning’ dimension of the IDEAL schedule, and the IDEAL 
manual that has just been published includes guidance to do so for the MMSE [24]. Similarly, the 
FTD-FRS is more restricted than the IDEAL schedule in that it applies only to people with 
frontotemporal dementia, and does not cover as many domains, for example care aspects beyond 
self-care. Indeed, one key aspect of the IDEAL schedule is that it was developed to estimate the need 
for care, rather than functionality, as does the FTD-FRS and other functioning scales. 
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Conclusion 
The IDEAL schedule was developed in response to gaps within dementia staging, and takes a broad 
approach in that it covers a range of domains that extends beyond cognitive impairments (as some 
other dementia staging tools do), it is applicable to all types and stages of dementia, and it can be 
used by any health care professional, both within clinical practice and research. The schedule’s 
reliability and validity has already been established in a wide range of settings using different 
language versions, though we invite others’ to test the schedule in further contexts. In addition, the 
schedule is unique in that it is accompanied by recommended priorities for interventions for the 
different symptoms and severity patterns of dementia – the ‘Menu of care options’.  
The IDEAL staging model is not in opposition, and may even be complementary, to other staging 
approaches, such as that based on biomarkers, or other staging tools that grade the severity of 
specific aspects of dementia, particularly cognitive functioning/impairment. We therefore hope that 
the IDEAL schedule will be used widely, to facilitate the assessment and staging of care for dementia, 
and ultimately improve the care for people with dementia. 
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Key points 
 The IDEAL schedule is a global staging model, which aims to guide the organisation of 
dementia care; covers a range of seven domains that extend beyond cognitive functioning 
and include care needs; is applicable to all types and stages of dementia; and can be used by 
any health care professional, both within clinical practice and research. 
 Other recent work on staging for dementia includes models based on biomarkers in 
Alzheimer’s disease, such as in the recently published research framework by the National 
Institute on Aging and Alzheimer’s Association (NIA-AA), or those based on specific aspects 
of dementia, principally cognitive impairment, for example the Mini-Mental State 
Examination (MMSE) or Clinical Dementia Rating Scale (CDR). 
 The IDEAL schedule is different to the staging models above, since it takes a broader 
approach in that it aims to help organise care for any type and stage of dementia regardless 
of the clinical presentation and underlying aetiology; and it covers not only the degree of 
cognitive impairment, but also related behavioural and psychological symptoms and 
functional impairment, and all relevant domains associated with dementia and care needs. 
 However, the IDEAL schedule is not in opposition to, or may even be complementary to, 
these other staging models for dementia. 
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